

according to Regulation (EC) No. 1907/2006

Revision Date 26.05.2017

Version 5.5

Details of the supplier of the	safety data sheet
	data sheet.
	In compliance with the conditions described in the annex to this safety
Identified uses	Chemical for synthesis
.2 Relevant identified uses of th	ne substance or mixture and uses advised against
CAS-No.	616-45-5
REACH Registration Number	01-2119475471-37-xxxx
Product name	2-Pyrrolidone for synthesis
Catalogue No.	807041

2.1 Classification of the substance or mixture Classification (REGULATION (EC) No 1272/2008)

Eye irritation, Category 2, H319

For the full text of the H-Statements mentioned in this Section, see Section 16.

according to Regulation (EC) No. 1907/2006

Catalogue No.

Product name

807041 2-Pyrrolidone for synthesis

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms



Signal word Warning

Hazard statements H319 Causes serious eye irritation.

Precautionary statements

Response

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

Reduced labelling (≤125 ml)

Hazard pictograms



Signal word Warning

CAS-No. 616-45-5

2.3 Other hazards

None known.

SECTION 3. Composition/information on ingredients

3.1 Substance

according to Regulation (EC) No. 1907/2006

Catalogue No.	807	/041	
Product name	2-P	yrrolidone for synthesis	
Formula	C₄H ₇ N	C₄H7NO (Hill)	
EC-No.	210-48	83-1	
Molar mass	85,11	85,11 g/mol	
Hazardous co	mponents (REGULATIO	N (EC) No 1272/2008)	
Chemical nam	ne (Concentration)		
CAS-No.	Registration number	Classification	
2-pyrrolidinone	e <i>(<= 100 %)</i>		
Substance does i	not meet the criteria for PBT or	vPvB according to Regulation (EC) No 1907/2006, Annex XIII.	
616-45-5	01-2119475471-37-		
	XXXX	Eye irritation, Category 2, H319	

For the full text of the H-Statements mentioned in this Section, see Section 16.

3.2 Mixture

Not applicable

SECTION 4. First aid measures

4.1 Description of first aid measures

After inhalation: fresh air.

In case of skin contact: Take off immediately all contaminated clothing. Rinse skin with water/ shower.

After eye contact: rinse out with plenty of water. Call in ophthalmologist. Remove contact lenses.

After swallowing: immediately make victim drink water (two glasses at most). Consult a physician.

4.2 Most important symptoms and effects, both acute and delayed

irritant effects

4.3 Indication of any immediate medical attention and special treatment needed

No information available.

according to Regulation (EC) No. 1907/2006

Catalogue No.

Product name

807041

2-Pyrrolidone for synthesis

SECTION 5. Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media Water, Foam, Carbon dioxide (CO2), Dry powder

Unsuitable extinguishing media

For this substance/mixture no limitations of extinguishing agents are given.

5.2 Special hazards arising from the substance or mixture

Combustible.

Vapours are heavier than air and may spread along floors.

Forms explosive mixtures with air on intense heating.

Development of hazardous combustion gases or vapours possible in the event of fire.

Fire may cause evolution of:

nitrogen oxides

5.3 Advice for firefighters

Special protective equipment for firefighters In the event of fire, wear self-contained breathing apparatus.

Further information

Suppress (knock down) gases/vapours/mists with a water spray jet. Prevent fire extinguishing water from contaminating surface water or the ground water system.

SECTION 6. Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Advice for non-emergency personnel: Avoid substance contact. Avoid inhalation of vapours/aerosols or dusts. Ensure adequate ventilation. Evacuate the danger area, observe emergency procedures, consult an expert.

Advice for emergency responders:

Protective equipment see section 8.

6.2 Environmental precautions

The Safety Data Sheets for catalogue items are available at www.merckgroup.com

according to Regulation (EC) No. 1907/2006

Catalogue No.807041Product name2-Pyrrolidone for synthesis

Do not let product enter drains.

6.3 Methods and materials for containment and cleaning up

Cover drains. Collect, bind, and pump off spills. Observe possible material restrictions (see sections 7 and 10). Depending on the state of matter, take up with suitable equipment or with liquid-absorbent material (e.g. Chemizorb®). Dispose of properly. Clean up affected area.

6.4 Reference to other sections

Indications about waste treatment see section 13.

SECTION 7. Handling and storage

7.1 Precautions for safe handling

Advice on safe handling Observe label precautions.

Hygiene measures

Change contaminated clothing. Wash hands after working with substance.

7.2 Conditions for safe storage, including any incompatibilities

Storage conditions

Dry.

Tightly closed.

Recommended storage temperature see product label.

7.3 Specific end use(s)

See exposure scenario in the Annex to this MSDS.

SECTION 8. Exposure controls/personal protection

8.1 Control parameters

according to Regulation (EC) No. 1907/2006

Catalogue No.	807041		
Product name	2-Pyrrolidor	ne for synthesis	
Derived No Effect Leve	el (DNEL)		
Worker DNEL, acute	Systemic effects	dermal	277 mg/kg Body weight
Worker DNEL, longterm	Systemic effects	dermal	10 mg/kg Body weight
Worker DNEL, longterm	Systemic effects	inhalation	57,8 mg/m³
Consumer DNEL, acute	Systemic effects	dermal	167 mg/kg Body weight
Consumer DNEL, acute	Systemic effects	oral	33,3 mg/kg Body weight
Consumer DNEL, longterm	Systemic effects	dermal	6 mg/kg Body weight
Consumer DNEL, longterm	Systemic effects	oral	5,2 mg/kg Body weight
Consumer DNEL, longterm	Systemic effects	inhalation	17,1 mg/m³
Predicted No Effect Co	oncentration (PNEC)		
PNEC Fresh water		0,5 mg/l	
PNEC Marine water		0,05 mg/l	
PNEC Aquatic intermittent re	elease	0,5 mg/l	
PNEC Fresh water sediment	t	0,42 mg/kg	
PNEC Soil		0,0612 mg/kg	
PNEC Sewage treatment pla	ant	10 mg/l	

8.2 Exposure controls

Engineering measures

Technical measures and appropriate working operations should be given priority over the use of personal protective equipment.

See section 7.1.

according to Regulation (EC) No. 1907/2006

Catalogue No.	807041
Product name	2-Pyrrolidone for synthesis

Individual protection measures

Protective clothing needs to be selected specifically for the workplace, depending on concentrations and quantities of the hazardous substances handled. The chemical resistance of the protective equipment should be enquired at the respective supplier.

Eye/face protection

Safety glasses

Hand protection

full contact:

Glove material:	polychloroprene
Glove thickness:	0,65 mm
Break through time:	> 480 min

splash contact:

Glove material:	natural latex
Glove thickness:	0,6 mm
Break through time:	> 120 min

The protective gloves to be used must comply with the specifications of EC Directive 89/686/EEC and the related standard EN374, for example KCL 720 Camapren® (full contact), KCL 706 Lapren® (splash contact).

The breakthrough times stated above were determined by KCL in laboratory tests acc. to EN374 with samples of the recommended glove types.

This recommendation applies only to the product stated in the safety data sheet<(>,<)> supplied by us and for the designated use. When dissolving in or mixing with other substances and under conditions deviating from those stated in EN374 please contact the supplier of CE-approved gloves (e.g. KCL GmbH, D-36124 Eichenzell, Internet: www.kcl.de).

Other protective equipment protective clothing

Respiratory protection

required when dusts/vapours/aerosols are generated.

Recommended Filter type: Filter A (acc. to DIN 3181) for vapours of organic compounds The entrepeneur has to ensure that maintenance, cleaning and testing of respiratory protective devices are carried out according to the instructions of the producer. These measures have to be properly documented.

according to Regulation (EC) No. 1907/2006

Catalogue No.807041Product name2-Pyrrolidone for synthesis

Environmental exposure controls

Do not let product enter drains.

SECTION 9. Physical and chemical properties

9.1 Information on basic physical and chemical properties

Form	solid
Colour	colourless
Odour	weak characteristic odour
Odour Threshold	not determined
рН	9 - 11 at 100 g/l 20 °C
Melting point	25,5 °C at 1.013 hPa (External MSDS)
Boiling point/boiling range	250 °C at 1.013 hPa
Flash point	138 °C Method: DIN 51758
Evaporation rate	No information available.
Flammability (solid, gas)	No information available.
Lower explosion limit	1,8 %(V)

according to Regulation (EC) No. 1907/2006

Catalogue No.	807041
Product name	2-Pyrrolidone for synthesis
Upper explosion limit	16,6 %(V)
Vapour pressure	0,04 hPa
	at 20 °C
	2 hPa
	at 80 °C
Relative vapour density	No information available.
Density	1,11 g/cm3
	at 20 °C
Deletine demeite	
Relative density	No information available.
Water solubility	at 20 °C
	soluble
Partition coefficient: n-	log Pow: -0,71 (25 °C)
octanol/water	OECD Test Guideline 107
	Bioaccumulation is not expected.
Auto invition to manage the	not auto-flammable
Auto-ignition temperature	not auto-nammable
Decomposition temperature	> 240 °C
F F	
Viscosity, dynamic	16,4 mPa.s
	at 26 °C
Explosive properties	Not classified as explosive.
Ovidining proportion	
Oxidizing properties	none

9.2 Other data

according to Regulation (EC) No. 1907/2006

Catalogue No.	807041
Product name	2-Pyrrolidone for synthesis
Ignition temperature	395 °C
	Method: DIN 51794
	Method: DIN 51794

SECTION 10. Stability and reactivity

10.1 Reactivity

Forms explosive mixtures with air on intense heating.

A range from approx. 15 Kelvin below the flash point is to be rated as critical.

The following applies in general to flammable organic substances and mixtures: in

correspondingly fine distribution, when whirled up a dust explosion potential may generally be assumed.

10.2 Chemical stability

The product is chemically stable under standard ambient conditions (room temperature) .

10.3 Possibility of hazardous reactions

Violent reactions possible with:

Strong oxidizing agents

10.4 Conditions to avoid

Strong heating.

10.5 Incompatible materials

no information available

10.6 Hazardous decomposition products

in the event of fire: See section 5.

according to Regulation (EC) No. 1907/2006

Catalogue No.

Product name

807041

2-Pyrrolidone for synthesis

SECTION 11. Toxicological information

11.1 Information on toxicological effects

Acute oral toxicity LD50 Rat: > 2.000 mg/kg OECD Test Guideline 401

Acute inhalation toxicity LC0 Rat: 0,061 mg/l; 8 h ; vapour OECD Test Guideline 403 (highest concentration to be prepared)

Symptoms: Possible symptoms:, mucosal irritations

Acute dermal toxicity LD50 Rabbit: > 2.000 mg/kg OECD Test Guideline 402

Skin irritation Rabbit Result: No skin irritation OECD Test Guideline 404

Eye irritation Rabbit Result: Eye irritation OECD Test Guideline 405 Causes serious eye irritation.

Sensitisation Patch test: human Result: negative

(IUCLID)

according to Regulation (EC) No. 1907/2006

Catalogue No.807041Product name2-Pyrrolidone for synthesis

Sensitisation test: Mouse Result: negative Method: OECD Test Guideline 429

The value is given in analogy to the following substances: 1-ethylpyrrolidin-2-one

Germ cell mutagenicity Genotoxicity in vivo In vivo micronucleus test Mouse male and female Intraperitoneal injection Bone marrow Result: negative Method: OECD Test Guideline 474

Genotoxicity in vitro
Ames test
Salmonella typhimurium
Result: negative

(ECHA)

In vitro mammalian cell gene mutation test Result: negative Method: OECD Test Guideline 476 Mutagenicity (mammal cell test): chromosome aberration. Human lymphocytes Result: negative Method: OECD Test Guideline 473 *Carcinogenicity*

No substantiated information from toxicological studies available.

Reproductive toxicity

Animal testing did not show any effects on fertility.

according to Regulation (EC) No. 1907/2006

Catalogue No.	807041
Product name	2-Pyrrolidone for synthesis

Teratogenicity

Did not show teratogenic effects in animal experiments.

Specific target organ toxicity - single exposure This information is not available.

Specific target organ toxicity - repeated exposure This information is not available.

Aspiration hazard

This information is not available.

11.2 Further information

Other dangerous properties can not be excluded. Handle in accordance with good industrial hygiene and safety practice.

SECTION 12. Ecological information

12.1 Toxicity

Toxicity to fish static test LC50 Danio rerio (zebra fish): > 4.600 mg/l; 96 h Analytical monitoring: yes OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates static test EC50 Daphnia magna (Water flea): > 500 mg/l; 48 h Directive 67/548/EEC, Annex V, C.2.

Toxicity to algae static test IC50 Desmodesmus subspicatus (green algae): > 500 mg/l; 72 h DIN 38412

Toxicity to bacteria static test EC50 activated sludge: > 1.000 mg/l; 0,5 h OECD Test Guideline 209

12.2 Persistence and degradability

Biodegradability ca. 98 %; 9 d; aerobic OECD Test Guideline 302B Readily eliminated from water

according to Regulation (EC) No. 1907/2006

Catalogue No.807041Product name2-Pyrrolidone for synthesis

Biochemical Oxygen Demand (BOD) 1.200 mg/g

(External MSDS)

Adsorbed organic bound halogens (AOX) Product does not contain any organic halogens.

12.3 Bioaccumulative potential

Partition coefficient: n-octanol/water log Pow: -0,71 (25 °C) OECD Test Guideline 107

Bioaccumulation is not expected.

12.4 Mobility in soil

No information available.

12.5 Results of PBT and vPvB assessment

Substance does not meet the criteria for PBT or vPvB according to Regulation (EC) No 1907/2006, Annex XIII.

12.6 Other adverse effects

Discharge into the environment must be avoided.

SECTION 13. Disposal considerations

Waste treatment methods

See www.retrologistik.com for processes regarding the return of chemicals and containers, or contact us there if you have further questions.

SECTION 14. Transport information

Land transport (ADR/RID)

14.1 - 14.6

Not classified as dangerous in the meaning of transport regulations.

Inland waterway transport (ADN)

Not relevant

according to Regulation (EC) No. 1907/2006

atalogue No.	807041
oduct name	2-Pyrrolidone for synthesis
Air transport (IATA)	
14.1 - 14.6	Not classified as dangerous in the meaning of transport regulations.
Sea transport (IMDG)	
14.1 - 14.6	Not classified as dangerous in the meaning of transport regulations.

SECTION 15. Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations		
Major Accident Hazard	SEVESO III	
Legislation	Not applicable	
Occupational restrictions	Take note of Dir 94/33 work.	B/EC on the protection of young people at
Regulation (EC) No 1005/2009 on substances that not		not regulated
deplete the ozone layer		
Regulation (EC) No 850/2004	of the European	not regulated
Parliament and of the Council	of 29 April 2004 on	
persistent organic pollutants a	and amending	
Directive 79/117/EEC		
Substances of very high concern (SVHC)		This product does not contain substances
		of very high concern according to
		Regulation (EC) No 1907/2006 (REACH),
		Article 57 above the respective regulatory
		concentration limit of \geq 0.1 % (w/w).
National legislation		
Storage class	10 - 13	

according to Regulation (EC) No. 1907/2006

Catalogue No.807041Product name2-Pyrrolidone for synthesis

15.2 Chemical safety assessment

For this product a chemical safety assessment was not carried out.

SECTION 16. Other information

Full text of H-Statements referred to under sections 2 and 3.

H319 Causes serious eye irritation.

Training advice

Provide adequate information, instruction and training for operators.

Labelling

Hazard pictograms



Signal word Warning

Hazard statements H319 Causes serious eye irritation.

Precautionary statements

Response

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

Key or legend to abbreviations and acronyms used in the safety data sheet

according to Regulation (EC) No. 1907/2006

Catalogue No.807041Product name2-Pyrrolidone for synthesis

Used abbreviations and acronyms can be looked up at www.wikipedia.org.

Regional representation

This information is given on the authorised Safety Data Sheet for your country.

The information contained herein is based on the present state of our knowledge. It characterises the product with regard to the appropriate safety precautions. It does not represent a guarantee of any properties of the product.

according to Regulation (EC) No. 1907/2006

Catalogue No.

Product name

807041 2-Pyrrolidone for synthesis

EXPOSURE SCENARIO 1 (Industrial use)

1. Industrial use Chemical for synthesis)

Sectors of end-use

SU 3	Industrial uses: Uses of substances as such or in preparations at industrial sites
SU9	Manufacture of fine chemicals
SU 10	Formulation [mixing] of preparations and/ or re-packaging (excluding alloys)

Chemical product category

- PC19 Intermediate
- PC21 Laboratory chemicals

Process categories

F100033 00	alegones
PROC1	Use in closed process, no likelihood of exposure
PROC2	Use in closed, continuous process with occasional controlled exposure
PROC3	Use in closed batch process (synthesis or formulation)
PROC4	Use in batch and other process (synthesis) where opportunity for exposure arises
PROC5	Mixing or blending in batch processes for formulation of preparations and articles
	(multistage and/ or significant contact)
PROC8a	Transfer of substance or preparation (charging/ discharging) from/ to vessels/ large
	containers at non-dedicated facilities
PROC8b	Transfer of substance or preparation (charging/ discharging) from/ to vessels/ large
	containers at dedicated facilities
PROC9	Transfer of substance or preparation into small containers (dedicated filling line, including
	weighing)
PROC10	Roller application or brushing
PROC15	Use as laboratory reagent
Environme	ental Release Categories
ERC2	Formulation of preparations
ERC4	Industrial use of processing aids in processes and products, not becoming part of articles
ERC6d	Industrial use of process regulators for polymerisation processes in production of resins,

The Safety Data Sheets for catalogue items are available at www.merckgroup.com

rubbers, polymers

according to Regulation (EC) No. 1907/2006

Catalogue No.	807041
Product name	2-Pyrrolidone for synthesis

2. Contributing scenarios: Operational conditions and risk management measures

2.1 Contributing scenario controlling worker exposure for: PROC1

Product characteristics

Covers the percentage of the substance in the product up to
100 %.
Low volatile liquid
<= 20 °C

Frequency and duration of use

Frequency of use	8 hours/day
Frequency of use	5 days/week

Other operational conditions affecting workers exposure

Conditions and measures related to personal protection, hygiene and health evaluation

Wear suitable gloves tested to EN374.

2.2 Contributing scenario controlling worker exposure for: PROC2, PROC3

Product characteristics

Concentration of the Substance in	Covers the percentage of the substance in the product up to
Mixture/Article	100 %.
Physical Form (at time of use)	Low volatile liquid
Process Temperature	<= 20 °C

Frequency and duration of use

Frequency of use	8 hours/day
Frequency of use	5 days/week

Other operational conditions affecting workers exposure

Outdoor / Indoor	Indoor with good general ventilation
------------------	--------------------------------------

according to Regulation (EC) No. 1907/2006

Catalogue No.	807041
Product name	2-Pyrrolidone for synthesis

Technical conditions and measures

Avoid dip sampling. Ensure material transfers are under containment or extract ventilation.

Organisational measures to prevent /limit releases, dispersion and exposure

Clear up spills immediately and dispose of waste safely.

Conditions and measures related to personal protection, hygiene and health evaluation

Wear suitable gloves tested to EN374.

2.3 Contributing scenario controlling worker exposure for: PROC4

Product characteristics

Concentration of the Substance in Mixture/Article	Covers the percentage of the substance in the product up to 100 %.
Physical Form (at time of use)	Low volatile liquid
Process Temperature	<= 20 °C

Frequency and duration of use

Frequency of use	8 hours/day
Frequency of use	5 days/week

Other operational conditions affecting workers exposure

Outdoor / Indoor Indoor Vith good general ventilation

Conditions and measures related to personal protection, hygiene and health evaluation

Wear suitable gloves tested to EN374.

2.4 Contributing scenario controlling worker exposure for: PROC5

Product characteristics

Concentration of the Substance in	Covers the percentage of the substance in the product up to
Mixture/Article	100 %.
Physical Form (at time of use)	Low volatile liquid
Process Temperature	<= 20 °C

according to Regulation (EC) No. 1907/2006

Catalogue No.	807041
Product name	2-Pyrrolidone for synthesis

Frequency and duration of use

Frequency of use	8 hours/day
Frequency of use	5 days/week

Other operational conditions affecting workers exposure

Outdoor / Indoor Indoor With local exhaust ventilation (LEV)

Organisational measures to prevent /limit releases, dispersion and exposure

Avoid manual contact with wet work pieces.

Conditions and measures related to personal protection, hygiene and health evaluation

Wear suitable gloves tested to EN374.

2.5 Contributing scenario controlling worker exposure for: PROC8a

Product characteristics

Concentration of the Substance in	Covers the percentage of the substance in the product up to
Mixture/Article	100 %.
Physical Form (at time of use)	Low volatile liquid
Process Temperature	<= 20 °C

Frequency and duration of use

Frequency of use	8 hours/day
Frequency of use	5 days/week

Other operational conditions affecting workers exposure

Outdoor / Indoor Indoor Indoor Vithout local exhaust ventilation (L

Technical conditions and measures

Clear transfer lines prior to de-coupling. Transfer via enclosed lines.

Organisational measures to prevent /limit releases, dispersion and exposure

Apply vessel entry procedures including use of forced supplied air. Clear up spills immediately and dispose of waste safely.

according to Regulation (EC) No. 1907/2006

Catalogue No.807041Product name2-Pyrrolidone for synthesis

Conditions and measures related to personal protection, hygiene and health evaluation

Wear suitable gloves tested to EN374.

2.6 Contributing scenario controlling worker exposure for: PROC8b

Product characteristics

Concentration of the Substance in	Covers the percentage of the substance in the product up to
Mixture/Article	100 %.
Physical Form (at time of use)	Low volatile liquid
Process Temperature	<= 20 °C

Frequency and duration of use

Frequency of use	8 hours/day
Frequency of use	5 days/week

Other operational conditions affecting workers exposure

Outdoor / Indoor Indoor Indoor with good general ventilation

Technical conditions and measures

Clear transfer lines prior to de-coupling.

Organisational measures to prevent /limit releases, dispersion and exposure

Ensure operatives are trained to minimise exposures.

Conditions and measures related to personal protection, hygiene and health evaluation

Wear suitable gloves tested to EN374.

2.7 Contributing scenario controlling worker exposure for: PROC9

Product characteristics Concentration of the Substance in Covers the percentage of the substance in the product up to Mixture/Article 100 %. Physical Form (at time of use) Low volatile liquid

according to Regulation (EC) No. 1907/2006

Catalogue No.	807041
Product name	2-Pyrrolidone for synthesis
Process Temperature	<= 20 °C
Frequency and duration of use	
Frequency of use	8 hours/day
Frequency of use	5 days/week
Other operational conditions affecting	g workers exposure
Outdoor / Indoor	Indoor without local exhaust ventilation (LEV)
Remarks	Ensure material transfers are under containment or extract
	ventilation.
Technical conditions and measures	
Clear transfer lines prior to de-coup	ling.
Put lids on containers immediately a Conditions and measures related to p	personal protection, hygiene and health evaluation
Put lids on containers immediately a Conditions and measures related to p Wear suitable gloves tested to EN3	after use. personal protection, hygiene and health evaluation 74.
Put lids on containers immediately a Conditions and measures related to p	after use. personal protection, hygiene and health evaluation 74.
Put lids on containers immediately a Conditions and measures related to p Wear suitable gloves tested to EN3	after use. personal protection, hygiene and health evaluation 74.
Put lids on containers immediately a Conditions and measures related to p Wear suitable gloves tested to EN3 2.8 Contributing scenario controlling v Product characteristics Concentration of the Substance in	after use. personal protection, hygiene and health evaluation 74. worker exposure for: PROC10 Covers the percentage of the substance in the product up to
Put lids on containers immediately a Conditions and measures related to p Wear suitable gloves tested to EN3 2.8 Contributing scenario controlling v Product characteristics	after use. personal protection, hygiene and health evaluation 74. worker exposure for: PROC10
Put lids on containers immediately a Conditions and measures related to p Wear suitable gloves tested to EN3 2.8 Contributing scenario controlling of Product characteristics Concentration of the Substance in	after use. personal protection, hygiene and health evaluation 74. worker exposure for: PROC10 Covers the percentage of the substance in the product up to
Put lids on containers immediately a Conditions and measures related to p Wear suitable gloves tested to EN3 2.8 Contributing scenario controlling v Product characteristics Concentration of the Substance in Mixture/Article	after use. personal protection, hygiene and health evaluation 74. worker exposure for: PROC10 Covers the percentage of the substance in the product up to 100 %.
Put lids on containers immediately a Conditions and measures related to p Wear suitable gloves tested to EN3 2.8 Contributing scenario controlling of Product characteristics Concentration of the Substance in Mixture/Article Physical Form (at time of use)	after use. personal protection, hygiene and health evaluation 74. worker exposure for: PROC10 Covers the percentage of the substance in the product up to 100 %. Low volatile liquid
Put lids on containers immediately a Conditions and measures related to p Wear suitable gloves tested to EN3 2.8 Contributing scenario controlling v Product characteristics Concentration of the Substance in Mixture/Article Physical Form (at time of use) Process Temperature	after use. personal protection, hygiene and health evaluation 74. worker exposure for: PROC10 Covers the percentage of the substance in the product up to 100 %. Low volatile liquid
Put lids on containers immediately a Conditions and measures related to p Wear suitable gloves tested to EN3 2.8 Contributing scenario controlling v Product characteristics Concentration of the Substance in Mixture/Article Physical Form (at time of use) Process Temperature Frequency and duration of use	after use. personal protection, hygiene and health evaluation 74. worker exposure for: PROC10 Covers the percentage of the substance in the product up to 100 %. Low volatile liquid <= 20 °C
Put lids on containers immediately a Conditions and measures related to p Wear suitable gloves tested to EN3 2.8 Contributing scenario controlling v Product characteristics Concentration of the Substance in Mixture/Article Physical Form (at time of use) Process Temperature Frequency and duration of use Frequency of use	after use. personal protection, hygiene and health evaluation 74. worker exposure for: PROC10 Covers the percentage of the substance in the product up to 100 %. Low volatile liquid <= 20 °C 8 hours/day 5 days/week

according to Regulation (EC) No. 1907/2006

Catalogue No.807041Product name2-Pyrrolidone for synthesis

Technical conditions and measures

Use long handled tools where possible.

Conditions and measures related to personal protection, hygiene and health evaluation

Wear chemically resistant gloves (tested to EN374) in combination with 'basic' employee training.

2.9 Contributing scenario controlling worker exposure for: PROC15

Product characteristics				
Concentration of the Substance in	Covers the percentage of the substance in the product up to			
Mixture/Article	100 %.			
Physical Form (at time of use)	Low volatile liquid			
Process Temperature	<= 20 °C			
Frequency and duration of use				
Frequency of use	8 hours/day			
Frequency of use	5 days/week			
Other operational conditions affecting workers exposure				

Remarks Handle in a fume cupboard or under extract ventilation.

Conditions and measures related to personal protection, hygiene and health evaluation

Wear suitable gloves tested to EN374.

3. Exposure estimation and reference to its source

Environment

A chemical safety assessment was performed according REACH Article 14(3), Annex I, sections 3 (Environmental Hazard Assessment) and 4 (PBT/vPvB Assessment). As no hazard was identified, an exposure assessment and risk characterisation is not necessary (REACH Annex I section 5.0).

according to Regulation (EC) No. 1907/2006

Catalogue No.807041Product name2-Pyrrolidone for synthesis

Workers

2.1 PROC1 longterm, inhalative, systemic longterm, combined, systemic 0,03 ECETOC TRA 2 2.2 PROC2 longterm, inhalative, systemic 0,06 ECETOC TRA 2 2.2 PROC3 longterm, inhalative, systemic 0,06 ECETOC TRA 2 2.2 PROC3 longterm, inhalative, systemic 0,06 ECETOC TRA 2 2.2 PROC3 longterm, combined, systemic 0,20 ECETOC TRA 2 2.2 PROC3 longterm, inhalative, systemic 0,20 ECETOC TRA 2 2.3 PROC4 longterm, inhalative, systemic 0,21 ECETOC TRA 2 2.4 PROC5 longterm, inhalative, systemic 0,21 ECETOC TRA 2 10ngterm, combined, systemic 0,69 ECETOC TRA 2 10ngterm, combined, systemic 0,90 ECETOC TRA 2 10ngterm, inhalative, systemic 0,90 ECETOC TRA 2 10ngterm, inhalative, systemic 0,14 ECETOC TRA 2 10ngterm, inhalative, systemic 0,14 ECETOC TRA 2 10ngterm, inhalative, systemic 0,14 ECETOC TRA 2 10ngterm, inhalative, systemic 0,17 Conclude safe use. 2.5 PROC8a longterm, inhalative, systemic 0,18 10ngterm, inhalative, systemic 0,69	CS	Use descriptor	Exposure duration, route, effect	RCR	Exposure Assessment Method
longterm, combined, systemic0,032.2PROC2longterm, inhalative, systemic0,06ECETOC TRA 2longterm, dermal, systemic0,14ECETOC TRA 2longterm, combined, systemic0,03ECETOC TRA 2longterm, combined, systemic0,03ECETOC TRA 2longterm, dermal, systemic0,03ECETOC TRA 2longterm, combined, systemic0,21ECETOC TRA 2longterm, dermal, systemic0,69ECETOC TRA 2longterm, dermal, systemic0,69ECETOC TRA 2longterm, dermal, systemic0,900,902.4PROC5longterm, inhalative, systemic0,14longterm, dermal, systemic0,14ECETOC TRA 2longterm, dermal, systemic0,14ECETOC TRA 2longterm, dermal, systemic0,17Cualitative assessment used to conclude safe use.2.5PROC8alongterm, inhalative, systemic0,09ECETOC TRA 2longterm, dermal, systemic0,09ECETOC TRA 2longterm, dermal, systemic0,17Cualitative assessment used to conclude safe use.2.6PROC8blongterm, inhalative, systemic0,09ECETOC TRA 2longterm, dermal, systemic0,03ECETOC TRA 2longterm, dermal, systemic0,69ECETOC TRA 2	2.1	PROC1	longterm, inhalative, systemic	< 0,01	ECETOC TRA 2
2.2 PROC2 longterm, inhalative, systemic 0.06 ECETOC TRA 2 longterm, dermal, systemic 0.14 ECETOC TRA 2 longterm, combined, systemic 0.20 2.2 PROC3 longterm, inhalative, systemic 0.03 ECETOC TRA 2 longterm, dermal, systemic 0.03 ECETOC TRA 2 longterm, inhalative, systemic 0.21 ECETOC TRA 2 longterm, dermal, systemic 0.69 ECETOC TRA 2 longterm, dermal, systemic 0.90 ECETOC TRA 2 longterm, dermal, systemic 0.14 ECETOC TRA 2 longterm, dermal, systemic 0.17 Qualitative assessment used to conclude safe use. 2.6 PROC8b longterm, inhalati			longterm, dermal, systemic	0,03	ECETOC TRA 2
2.2PROC3Iongterm, dermal, systemic longterm, oombined, systemic longterm, dermal, systemic0,14ECETOC TRA 2 LORDERT, dermal, systemic 0,202.2PROC3Iongterm, inhalative, systemic longterm, combined, systemic0,18ECETOC TRA 2 ECETOC TRA 2 LORDERT, dermal, systemic longterm, dermal, systemic longterm, dermal, systemic0,21ECETOC TRA 2 ECETOC TRA 2 ECETOC TRA 2 LORDERT, dermal, systemic longterm, dermal, systemic longterm, dermal, systemic longterm, dermal, systemic0,03ECETOC TRA 2 ECETOC TRA 2 LORDERT, dermal, systemic longterm, de			longterm, combined, systemic	0,03	
2.2PROC3Iongterm, combined, systemic longterm, dermal, systemic longterm, combined, systemic0,18 0,03 CETOC TRA 2 ECETOC TRA 2 ECETOC TRA 22.3PROC4Iongterm, dermal, systemic longterm, combined, systemic0,21ECETOC TRA 2 ECETOC TRA 2 ECETOC TRA 22.4PROC5Iongterm, inhalative, systemic longterm, combined, systemic0,03ECETOC TRA 2 ECETOC TRA 22.4PROC5Iongterm, inhalative, systemic longterm, combined, systemic0,14ECETOC TRA 2 ECETOC TRA 22.5PROC8aIongterm, inhalative, systemic longterm, dermal, systemic0,14ECETOC TRA 2 ECETOC TRA 22.6PROC8aIongterm, inhalative, systemic longterm, dermal, systemic0,09ECETOC TRA 2 ECETOC TRA 22.6PROC8bIongterm, inhalative, systemic longterm, dermal, systemic0,09ECETOC TRA 2 ECETOC TRA 22.7PROC9Iongterm, inhalative, systemic longterm, dermal, systemic0,03ECETOC TRA 2 ECETOC TRA 22.7PROC9Iongterm, inhalative, systemic longterm, dermal, systemic longterm, dermal, systemic0,03ECETOC TRA 2 ECETOC TRA 22.8PROC10Iongterm, inhalative, systemic longterm, dermal, systemic longterm, dermal, systemic0,14ECETOC TRA 22.9PROC15Iongterm, inhalative, systemic longterm, dermal, systemic longterm, dermal, systemic0,18ECETOC TRA 22.9PROC15Iongterm, inhalative, systemic longterm, dermal, systemic longterm, dermal, systemic0,03ECETOC TRA 22.9	2.2	PROC2	longterm, inhalative, systemic	0,06	ECETOC TRA 2
2.2PROC3longterm, inhalative, systemic longterm, dermal, systemic longterm, combined, systemic0,18ECETOC TRA 2 ECETOC TRA 2 longterm, dermal, systemic2.3PROC4longterm, inhalative, systemic longterm, combined, systemic0,21ECETOC TRA 2 ECETOC TRA 2 longterm, dermal, systemic2.4PROC5longterm, inhalative, systemic longterm, dermal, systemic0,03ECETOC TRA 2 ECETOC TRA 2 longterm, dermal, systemic2.4PROC5longterm, inhalative, systemic longterm, dermal, systemic0,03ECETOC TRA 2 ECETOC TRA 2 longterm, dermal, systemic2.5PROC8alongterm, inhalative, systemic longterm, dermal, systemic0,09ECETOC TRA 2 Conclude safe use.2.6PROC8blongterm, inhalative, systemic longterm, dermal, systemic0,09ECETOC TRA 2 conclude safe use.2.6PROC8blongterm, inhalative, systemic longterm, dermal, systemic0,09ECETOC TRA 2 conclude safe use.2.7PROC9longterm, inhalative, systemic longterm, dermal, systemic0,03ECETOC TRA 2 longterm, dermal, systemic2.8PROC10longterm, inhalative, systemic longterm, dermal, systemic0,18ECETOC TRA 22.8PROC10longterm, inhalative, systemic longterm, dermal, systemic0,18ECETOC TRA 22.9PROC15longterm, inhalative, systemic longterm, dermal, systemic0,03ECETOC TRA 22.9PROC15longterm, inhalative, systemic longterm, dermal, systemic0,03ECETOC TRA 22.9PROC15l			longterm, dermal, systemic	0,14	ECETOC TRA 2
Iongterm, dermal, systemic longterm, combined, systemic0.03 0.21ECETOC TRA 2 ECETOC TRA 2 ECETOC TRA 2 ECETOC TRA 2 longterm, dermal, systemic0.69 0.69ECETOC TRA 2 ECETOC TRA 2 longterm, dermal, systemic2.4PROC5longterm, inhalative, systemic longterm, dermal, systemic0.03 0.90ECETOC TRA 2 ECETOC TRA 2 longterm, dermal, systemic2.4PROC5longterm, inhalative, systemic longterm, dermal, systemic longterm, combined, systemic0.03 0.03ECETOC TRA 2 ECETOC TRA 2 longterm, dermal, systemic 0.1142.5PROC8alongterm, inhalative, systemic longterm, dermal, systemic0.09ECETOC TRA 2 conclude safe use. Qualitative assessment used to conclude safe use.2.6PROC8blongterm, inhalative, systemic longterm, dermal, systemic0.09ECETOC TRA 2 conclude safe use.2.6PROC8blongterm, inhalative, systemic longterm, dermal, systemic0.09ECETOC TRA 2 conclude safe use.2.6PROC9longterm, inhalative, systemic longterm, dermal, systemic0.03ECETOC TRA 2 ECETOC TRA 2 longterm, dermal, systemic2.7PROC9longterm, inhalative, systemic longterm, dermal, systemic0.03ECETOC TRA 22.8PROC10longterm, inhalative, systemic longterm, dermal, systemic0.18ECETOC TRA 22.9PROC15longterm, inhalative, systemic longterm, dermal, systemic0.03ECETOC TRA 22.9PROC15longterm, inhalative, systemic longterm, dermal, systemic0.03ECETOC TRA 22.9<			longterm, combined, systemic	0,20	
Iongterm, combined, systemic0.212.3PROC4longterm, inhalative, systemic0.69ECETOC TRA 2longterm, dermal, systemic0.900.902.4PROC5longterm, inhalative, systemic0.03ECETOC TRA 2longterm, dermal, systemic0.14ECETOC TRA 2longterm, dermal, systemic0.14ECETOC TRA 2longterm, dermal, systemic0.14ECETOC TRA 2longterm, dermal, systemic0.172.5PROC8alongterm, inhalative, systemic0.09longterm, dermal, systemic0.09ECETOC TRA 2longterm, dermal, systemic0.09ECETOC TRA 2longterm, dermal, systemic0.09ECETOC TRA 2longterm, dermal, systemic0.09ECETOC TRA 2longterm, dermal, systemic0.69ECETOC TRA 2longterm, dermal, systemic0.69ECETOC TRA 2longterm, dermal, systemic0.78ECETOC TRA 2longterm, dermal, systemic0.69ECETOC TRA 2longterm, dermal, systemic0.69ECETOC TRA 2longterm, combined, systemic0.72ECETOC TRA 2longterm, dermal, systemic0.74ECETOC TRA 2longterm, dermal, systemic0.72ECETOC TRA 2longterm, dermal, systemic0.74ECETOC TRA 2longterm, dermal, systemic0.72ECETOC TRA 2longterm, dermal, systemic0.73ECETOC TRA 2longterm, dermal, systemic0.32ECETOC TRA 2longterm, dermal, systemic0.33	2.2	PROC3	longterm, inhalative, systemic	0,18	ECETOC TRA 2
2.3 PROC4 longterm, inhalative, systemic 0,21 ECETOC TRA 2 longterm, dermal, systemic 0,69 ECETOC TRA 2 longterm, combined, systemic 0,90 ECETOC TRA 2 longterm, inhalative, systemic 0,03 ECETOC TRA 2 longterm, inhalative, systemic 0,14 ECETOC TRA 2 longterm, dermal, systemic 0,14 ECETOC TRA 2 longterm, dermal, systemic 0,14 ECETOC TRA 2 longterm, dermal, systemic 0,17 Coualitative assessment used to conclude safe use. 2.5 PROC8a longterm, inhalative, systemic 0,09 ECETOC TRA 2 longterm, dermal, systemic 0,09 ECETOC TRA 2 Qualitative assessment used to conclude safe use. 2.6 PROC8b longterm, inhalative, systemic 0,69 ECETOC TRA 2 longterm, dermal, systemic 0,69 ECETOC TRA 2 Qualitative assessment used to conclude safe use. 2.7 PROC9 longterm, inhalative, systemic 0,78 ECETOC TRA 2 longterm, dermal, systemic 0,78 ECETOC TRA 2 Iongterm, inhalative, systemic 0,72 2.8 PROC10 longterm, inhalative, syst			longterm, dermal, systemic	0,03	ECETOC TRA 2
Iongterm, dermal, systemic longterm, combined, systemic0,69ECETOC TRA 22.4PROCSlongterm, inhalative, systemic longterm, dermal, systemic0,03ECETOC TRA 22.5PROC8alongterm, inhalative, systemic longterm, dermal, systemic0,14ECETOC TRA 22.5PROC8alongterm, inhalative, systemic longterm, dermal, systemic0,09ECETOC TRA 22.6PROC8blongterm, inhalative, systemic longterm, dermal, systemic0,09ECETOC TRA 22.6PROC8blongterm, inhalative, systemic longterm, dermal, systemic0,09ECETOC TRA 22.6PROC8blongterm, inhalative, systemic longterm, dermal, systemic0,09ECETOC TRA 22.6PROC9longterm, inhalative, systemic longterm, dermal, systemic0,09ECETOC TRA 22.7PROC9longterm, inhalative, systemic longterm, dermal, systemic0,18ECETOC TRA 22.8PROC10longterm, inhalative, systemic longterm, combined, systemic0,14ECETOC TRA 22.8PROC10longterm, inhalative, systemic longterm, combined, systemic0,18ECETOC TRA 22.9PROC15longterm, inhalative, systemic longterm, combined, systemic0,32ECETOC TRA 22.9PROC15longterm, inhalative, systemic longterm, combined, systemic0,03ECETOC TRA 22.9PROC15longterm, inhalative, systemic longterm, dermal, systemic0,03ECETOC TRA 22.9PROC15longterm, inhalative, systemic longterm, dermal, systemic<			longterm, combined, systemic	0,21	
2.4PROC5longterm, combined, systemic longterm, dermal, systemic longterm, combined, systemic0,03ECETOC TRA 22.4PROC5longterm, dermal, systemic longterm, combined, systemic0,14ECETOC TRA 22.5PROC8alongterm, inhalative, systemic longterm, dermal, systemic0,17Qualitative assessment used to conclude safe use. Qualitative assessment used to conclude safe use.2.6PROC8blongterm, inhalative, systemic longterm, dermal, systemic0,09ECETOC TRA 22.6PROC8blongterm, inhalative, systemic longterm, dermal, systemic0,09ECETOC TRA 22.7PROC9longterm, inhalative, systemic longterm, combined, systemic0,03ECETOC TRA 22.8PROC10longterm, inhalative, systemic longterm, combined, systemic0,18ECETOC TRA 22.8PROC10longterm, inhalative, systemic longterm, combined, systemic0,14ECETOC TRA 22.9PROC15longterm, inhalative, systemic longterm, dermal, systemic longterm, combined, systemic0,32ECETOC TRA 22.9PROC15longterm, inhalative, systemic longterm, dermal, systemic longterm, dermal, systemic0,03ECETOC TRA 22.9PROC15longterm, inhalative, systemic longterm, dermal, systemic longterm, dermal, systemic0,03ECETOC TRA 22.9PROC15longterm, inhalative, systemic longterm, dermal, systemic longterm, dermal, systemic0,03ECETOC TRA 2	2.3	PROC4	longterm, inhalative, systemic	0,21	ECETOC TRA 2
2.4 PROC5 longterm, inhalative, systemic longterm, dermal, systemic longterm, combined, systemic 0,03 ECETOC TRA 2 2.5 PROC8a longterm, inhalative, systemic longterm, dermal, systemic 0,17 Qualitative assessment used to conclude safe use. 2.5 PROC8a longterm, inhalative, systemic longterm, dermal, systemic 0,09 ECETOC TRA 2 2.6 PROC8b longterm, inhalative, systemic longterm, dermal, systemic 0,09 ECETOC TRA 2 2.6 PROC9 longterm, inhalative, systemic longterm, dermal, systemic 0,69 ECETOC TRA 2 2.7 PROC9 longterm, inhalative, systemic longterm, dermal, systemic 0,69 ECETOC TRA 2 2.8 PROC10 longterm, inhalative, systemic longterm, combined, systemic 0,18 ECETOC TRA 2 2.8 PROC10 longterm, inhalative, systemic longterm, combined, systemic 0,14 ECETOC TRA 2 2.8 PROC10 longterm, inhalative, systemic 0,14 ECETOC TRA 2 longterm, inhalative, systemic 0,14 ECETOC TRA 2 Iongterm, dermal, systemic 0,32 2.9 PROC15 longterm, inhalative, systemic 0,03 ECETOC TRA 2 longterm, dermal,			longterm, dermal, systemic	0,69	ECETOC TRA 2
Longterm, dermal, systemic0,14 0,17ECETOC TRA 2 0,172.5PROC8alongterm, inhalative, systemic0,172.5PROC8alongterm, inhalative, systemicQualitative assessment used to conclude safe use.2.6PROC8blongterm, inhalative, systemic0,09ECETOC TRA 2 Longterm, dermal, systemic2.6PROC8blongterm, inhalative, systemic0,09ECETOC TRA 2 Longterm, dermal, systemic2.7PROC9longterm, inhalative, systemic0,03ECETOC TRA 2 Longterm, dermal, systemic2.8PROC10longterm, inhalative, systemic0,03ECETOC TRA 2 Longterm, dermal, systemic2.8PROC10longterm, inhalative, systemic0,14ECETOC TRA 2 Longterm, dermal, systemic2.9PROC15longterm, inhalative, systemic0,03ECETOC TRA 2 Longterm, dermal, systemic			longterm, combined, systemic	0,90	
Iongterm, combined, systemic0,172.5PROC8alongterm, inhalative, systemicQualitative assessment used to conclude safe use. Qualitative assessment used to conclude safe use.2.6PROC8blongterm, inhalative, systemic0,09ECETOC TRA 2100gterm, dermal, systemic0,69ECETOC TRA 2100gterm, dermal, systemic0,78Iongterm, dermal, systemic2.7PROC9longterm, inhalative, systemic0,03ECETOC TRA 2100gterm, dermal, systemic0,69ECETOC TRA 2100gterm, dermal, systemic0,69ECETOC TRA 2100gterm, dermal, systemic0,69ECETOC TRA 2100gterm, dermal, systemic0,69ECETOC TRA 2100gterm, combined, systemic0,72Iongterm, dermal, systemic2.8PROC10longterm, inhalative, systemic0,14ECETOC TRA 2100gterm, combined, systemic0,32Iongterm, combined, systemic0,322.9PROC15longterm, inhalative, systemic0,03ECETOC TRA 2100gterm, dermal, systemic0,03ECETOC TRA 2100gterm, dermal, systemic0,32ICETOC TRA 2100gterm, dermal, systemic0,03ECETOC TRA 2100gterm, dermal, systemic<	2.4	PROC5	longterm, inhalative, systemic	0,03	ECETOC TRA 2
2.5 PROC8a longterm, inhalative, systemic Qualitative assessment used to conclude safe use. 0.0gterm, dermal, systemic 0.09 ECETOC TRA 2 2.6 PROC8b longterm, inhalative, systemic 0.09 ECETOC TRA 2 100 longterm, dermal, systemic 0.69 ECETOC TRA 2 100 longterm, dermal, systemic 0.78 2.7 PROC9 longterm, inhalative, systemic 0.03 ECETOC TRA 2 100 longterm, dermal, systemic 0.03 ECETOC TRA 2 100 longterm, dermal, systemic 0.03 ECETOC TRA 2 100 longterm, dermal, systemic 0.03 ECETOC TRA 2 100 longterm, inhalative, systemic 0.72 Ingterm, dermal, systemic 2.8 PROC10 longterm, inhalative, systemic 0.18 ECETOC TRA 2 100 longterm, dermal, systemic 0.32 Ingterm, dermal, systemic 0.32 2.9 PROC15 longterm, inhalative, systemic 0.03 ECETOC TRA 2 100 longterm, dermal, systemic 0.03 ECETOC TRA 2 100 longterm, dermal, systemic 0.32			longterm, dermal, systemic	0,14	ECETOC TRA 2
2.5 PROC8a longterm, inhalative, systemic conclude safe use. longterm, dermal, systemic 0,09 ECETOC TRA 2 2.6 PROC8b longterm, inhalative, systemic 0,09 ECETOC TRA 2 longterm, dermal, systemic 0,69 ECETOC TRA 2 longterm, combined, systemic 0,78 2.7 PROC9 longterm, inhalative, systemic 0,03 ECETOC TRA 2 longterm, dermal, systemic 0,03 ECETOC TRA 2 longterm, dermal, systemic 0,03 ECETOC TRA 2 longterm, dermal, systemic 0,14 ECETOC TRA 2 longterm, dermal, systemic 0,32 ECETOC TRA 2 longterm, inhalative, systemic 0,14 ECETOC TRA 2 longterm, combined, systemic 0,32 ECETOC TRA 2 longterm, dermal, systemic 0,32 ECETOC TRA 2 longterm, inhalative, systemic 0,03 ECETOC TRA 2 longterm, inhalative, systemic 0,03 ECETOC TRA 2 longterm, inhalative, systemic 0,03 ECETOC TRA 2 longterm, dermal, systemic 0,03 ECETOC TRA 2 longterm, inhalative, systemic 0,03			longterm, combined, systemic	0,17	
Longterm, dermal, systemicconclude safe use.2.6PROC8blongterm, inhalative, systemic0,09ECETOC TRA 2longterm, dermal, systemic0,69ECETOC TRA 2longterm, combined, systemic0,782.7PROC9longterm, inhalative, systemic0,03ECETOC TRA 2longterm, dermal, systemic0,69ECETOC TRA 2longterm, dermal, systemic0,69ECETOC TRA 2longterm, combined, systemic0,72ECETOC TRA 2longterm, combined, systemic0,72Iongterm, combined, systemiclongterm, combined, systemic0,18ECETOC TRA 2longterm, dermal, systemic0,14ECETOC TRA 2longterm, combined, systemic0,32Iongterm, combined, systemiclongterm, combined, systemic0,03ECETOC TRA 2longterm, combined, systemic0,03ECETOC TRA 2longterm, combined, systemic0,03ECETOC TRA 2longterm, combined, systemic0,03ECETOC TRA 2longterm, dermal, systemic0,03ECETOC TRA 2longterm, dermal, systemic0,03ECETOC TRA 2longterm, dermal, systemic0,03ECETOC TRA 2longterm, dermal, systemic0,01ECETOC TRA 2	2.5	PROC8a	longterm, inhalative, systemic		
Iongterm, dermal, systemic0,69ECETOC TRA 2Iongterm, combined, systemic0,782.7PROC9Iongterm, inhalative, systemic0,03ECETOC TRA 2Iongterm, dermal, systemic0,69ECETOC TRA 2Iongterm, combined, systemic0,722.8PROC10Iongterm, inhalative, systemic0,18ECETOC TRA 2Iongterm, dermal, systemic0,14ECETOC TRA 2Iongterm, dermal, systemic0,320,322.9PROC15Iongterm, inhalative, systemic0,03ECETOC TRA 2Iongterm, dermal, systemic0,03ECETOC TRA 2Iongterm, dermal, systemic0,03ECETOC TRA 2			longterm, dermal, systemic		
Iongterm, combined, systemic0,782.7PROC9Iongterm, inhalative, systemic0,03ECETOC TRA 2Iongterm, dermal, systemic0,69ECETOC TRA 2Iongterm, combined, systemic0,722.8PROC10Iongterm, inhalative, systemic0,18ECETOC TRA 2Iongterm, dermal, systemic0,14ECETOC TRA 2Iongterm, dermal, systemic0,14ECETOC TRA 2Iongterm, combined, systemic0,32	2.6	PROC8b	longterm, inhalative, systemic	0,09	ECETOC TRA 2
2.7 PROC9 longterm, inhalative, systemic 0,03 ECETOC TRA 2 longterm, dermal, systemic 0,69 ECETOC TRA 2 longterm, combined, systemic 0,72 2.8 PROC10 longterm, inhalative, systemic 0,18 ECETOC TRA 2 longterm, dermal, systemic 0,14 ECETOC TRA 2 longterm, dermal, systemic 0,14 ECETOC TRA 2 longterm, combined, systemic 0,32 0,32 2.9 PROC15 longterm, inhalative, systemic 0,03 ECETOC TRA 2 longterm, dermal, systemic 0,03 ECETOC TRA 2 longterm, combined, systemic 0,03 ECETOC TRA 2			longterm, dermal, systemic	0,69	ECETOC TRA 2
Iongterm, dermal, systemic 0,69 ECETOC TRA 2 Iongterm, combined, systemic 0,72 2.8 PROC10 Iongterm, inhalative, systemic 0,18 ECETOC TRA 2 Iongterm, dermal, systemic 0,14 ECETOC TRA 2 Iongterm, combined, systemic 0,32 2.9 PROC15 Iongterm, inhalative, systemic 0,03 Iongterm, dermal, systemic 0,03 ECETOC TRA 2 Iongterm, inhalative, systemic 0,03 ECETOC TRA 2			longterm, combined, systemic	0,78	
Iongterm, combined, systemic 0,72 2.8 PROC10 Iongterm, inhalative, systemic 0,18 ECETOC TRA 2 Iongterm, dermal, systemic 0,14 ECETOC TRA 2 Iongterm, combined, systemic 0,32 2.9 PROC15 Iongterm, inhalative, systemic 0,03 ECETOC TRA 2 Iongterm, dermal, systemic 0,03 ECETOC TRA 2 Iongterm, dermal, systemic 0,03 ECETOC TRA 2	2.7	PROC9	longterm, inhalative, systemic	0,03	ECETOC TRA 2
2.8 PROC10 longterm, inhalative, systemic 0,18 ECETOC TRA 2 longterm, dermal, systemic 0,14 ECETOC TRA 2 longterm, combined, systemic 0,32 2.9 PROC15 longterm, inhalative, systemic 0,03 longterm, dermal, systemic 0,03 ECETOC TRA 2 longterm, inhalative, systemic 0,03 ECETOC TRA 2 longterm, dermal, systemic 0,01 ECETOC TRA 2			longterm, dermal, systemic	0,69	ECETOC TRA 2
longterm, dermal, systemic 0,14 ECETOC TRA 2 longterm, combined, systemic 0,32 2.9 PROC15 longterm, inhalative, systemic 0,03 ECETOC TRA 2 longterm, dermal, systemic 0,03 ECETOC TRA 2 longterm, dermal, systemic 0,03 ECETOC TRA 2			longterm, combined, systemic	0,72	
2.9 PROC15 longterm, inhalative, systemic 0,03 ECETOC TRA 2 longterm, dermal, systemic < 0,01	2.8	PROC10	longterm, inhalative, systemic	0,18	ECETOC TRA 2
2.9 PROC15 longterm, inhalative, systemic 0,03 ECETOC TRA 2 longterm, dermal, systemic < 0,01			longterm, dermal, systemic	0,14	ECETOC TRA 2
longterm, dermal, systemic < 0,01 ECETOC TRA 2			longterm, combined, systemic	0,32	
	2.9	PROC15	longterm, inhalative, systemic	0,03	ECETOC TRA 2
longterm, combined, systemic 0,03			longterm, dermal, systemic	< 0,01	ECETOC TRA 2
			longterm, combined, systemic	0,03	

according to Regulation (EC) No. 1907/2006

Catalogue No.

Product name

807041 2-Pyrrolidone for synthesis

4. Guidance to Downstream User to evaluate whether he works inside the boundaries set by the Exposure Scenario

Please refer to the following documents: ECHA Guidance on information requirements and chemical safety assessment Chapter R.12: Use descriptor system; ECHA Guidance for downstream users; ECHA Guidance on information requirements and chemical safety assessment Part D: Exposure Scenario Building, Part E: Risk Characterisation and Part G: Extending the SDS; VCI/Cefic REACH Practical Guides on Exposure Assessment and Communications in the Supply Chain; CEFIC Guidance Specific Environmental Release Categories (SPERCs).

For scaling of worker exposure assessments performed with ECETOC TRA, please consult the Merck tool ScIDeEx® at www.merckmillipore.com/scideex.

according to Regulation (EC) No. 1907/2006

Catalogue No.807041Product name2-Pyrrolidone for synthesis

EXPOSURE SCENARIO 2 (Professional use)

1. Professional use Chemical for synthesis)

Sectors of end-use

SU 22 Professional uses: Public domain (administration, education, entertainment, services, craftsmen)

Chemical product category

PC21 Laboratory chemicals

Process categories

PROC15 Use as laboratory reagent

Environmental Release Categories

ERC8a	Wide dispersive indoor use of processing aids in open systems
ERC8c	Wide dispersive indoor use resulting in inclusion into or onto a matrix
ERC8d	Wide dispersive outdoor use of processing aids in open systems
ERC8f	Wide dispersive outdoor use resulting in inclusion into or onto a matrix

2. Contributing scenarios: Operational conditions and risk management measures

2.1 Contributing scenario controlling worker exposure for: PROC15

Product characteristics

Concentration of the Substance in	Covers the percentage of the substance in the product up to
Mixture/Article	100 %.
Physical Form (at time of use)	Low volatile liquid
Process Temperature	<= 20 °C

Frequency and duration of use

Frequency of use	8 hours/day
Frequency of use	5 days/week

Other operational conditions affecting workers exposure

Remarks Handle in a fume cupboard or under e	extract ventilation.
--	----------------------

according to Regulation (EC) No. 1907/2006

Catalogue No.807041Product name2-Pyrrolidone for synthesis

Conditions and measures related to personal protection, hygiene and health evaluation

Wear suitable gloves tested to EN374.

3. Exposure estimation and reference to its source

Environment

A chemical safety assessment was performed according REACH Article 14(3), Annex I, sections 3 (Environmental Hazard Assessment) and 4 (PBT/vPvB Assessment). As no hazard was identified, an exposure assessment and risk characterisation is not necessary (REACH Annex I section 5.0).

Workers

CS	Use descriptor	Exposure duration, route, effect	RCR	Exposure Assessment Method
2.1	PROC15	longterm, inhalative, systemic	0,03	ECETOC TRA 2
		longterm, dermal, systemic		Qualitative assessment used to conclude safe use.

4. Guidance to Downstream User to evaluate whether he works inside the boundaries set by the Exposure Scenario

Please refer to the following documents: ECHA Guidance on information requirements and chemical safety assessment Chapter R.12: Use descriptor system; ECHA Guidance for downstream users; ECHA Guidance on information requirements and chemical safety assessment Part D: Exposure Scenario Building, Part E: Risk Characterisation and Part G: Extending the SDS; VCI/Cefic REACH Practical Guides on Exposure Assessment and Communications in the Supply Chain; CEFIC Guidance Specific Environmental Release Categories (SPERCs).

For scaling of worker exposure assessments performed with ECETOC TRA, please consult the Merck tool ScIDeEx® at www.merckmillipore.com/scideex.